XOMA.O Stock Overview
Operates as a biotech royalty aggregator in the United States and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
XOMA Royalty Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.27 |
| 52 Week High | US$25.87 |
| 52 Week Low | US$22.06 |
| Beta | 0.90 |
| 11 Month Change | -1.36% |
| 3 Month Change | -0.68% |
| 1 Year Change | 13.53% |
| 33 Year Change | -3.43% |
| 5 Year Change | n/a |
| Change since IPO | 2.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| XOMA.O | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.3% | 4.0% | 2.2% |
| 1Y | 13.5% | 18.3% | 32.6% |
Return vs Industry: XOMA.O underperformed the US Biotechs industry which returned 18.3% over the past year.
Return vs Market: XOMA.O underperformed the US Market which returned 32.6% over the past year.
Price Volatility
| XOMA.O volatility | |
|---|---|
| XOMA.O Average Weekly Movement | 0.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: XOMA.O has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: XOMA.O's weekly volatility (1%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 13 | Owen Hughes | xoma.com |
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
XOMA Royalty Corporation Fundamentals Summary
| XOMA.O fundamental statistics | |
|---|---|
| Market cap | US$365.38m |
| Earnings (TTM) | -US$35.43m |
| Revenue (TTM) | US$21.61m |
18.5x
P/S Ratio-11.3x
P/E RatioIs XOMA.O overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XOMA.O income statement (TTM) | |
|---|---|
| Revenue | US$21.61m |
| Cost of Revenue | US$2.04m |
| Gross Profit | US$19.57m |
| Other Expenses | US$55.00m |
| Earnings | -US$35.43m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.01 |
| Gross Margin | 90.58% |
| Net Profit Margin | -164.00% |
| Debt/Equity Ratio | 139.0% |
How did XOMA.O perform over the long term?
See historical performance and comparison